Vivus signs impotence drug deal as proxy vote looms

(Reuters) – Vivus Inc, which is under intense pressure from its top shareholder over its marketing, said it signed a deal worth up to 95 million euros ($ 121.47 million) with Italy’s Menarini Group to introduce its erectile dysfunction drug in Europe, Australia and New Zealand. Vivus shares rose as much as 6 percent in morning trading on the Nasdaq before easing back to be up 2.5 percent in early afternoon trading. Privately held Menarini will sell the drug, avanafil, as Spedra in Australia, New Zealand and 40 European countries. …
Sexual Health News Headlines – Yahoo! News